Cagrilintide + Semaglutide
Cagrilintide + Semaglutide is a dual-mechanism metabolic blend combining a long-acting amylin analog with a GLP-1 receptor agonist for comprehensive appetite regulation and metabolic research. Cagrilintide targets amylin receptors to reduce appetite and suppress glucagon, while Semaglutide activates GLP-1 receptors to enhance insulin secretion and promote satiety. Phase II trials demonstrated 22.7% mean weight reduction versus 8.0% for semaglutide alone, highlighting the synergistic potential of dual amylin/GLP-1 co-agonism. Both compounds feature fatty acid conjugation for extended half-life, making this blend ideal for next-generation metabolic and body composition research.
This dual-mechanism metabolic blend combines Cagrilintide (5mg), a long-acting amylin analog targeting amylin receptors to reduce appetite and suppress glucagon, with Semaglutide (5mg), a GLP-1 receptor agonist. Phase II CagriSema investigations reported mean body-weight reductions of up to 22.7%, compared with 8.0% observed with semaglutide alone, while Phase III REDEFINE studies continue to evaluate the therapeutic potential of this combination. Dual amylin/GLP-1 co-agonism has emerged as a major area of interest in next-generation metabolic research.
Cagrilintide is a long-acting amylin analog (MW approximately 3934 g/mol; CAS 2295591-85-6) engineered with fatty acid conjugation to extend circulation time through albumin binding. Acting as an agonist at amylin receptors (AMY1–3), it mimics endogenous amylin activity by promoting satiety signaling, reducing food intake, and suppressing glucagon release. Its prolonged pharmacokinetic profile supports sustained receptor activation and once-weekly research dosing paradigms.
Semaglutide is a 29-amino-acid GLP-1 analog (MW 4113.6 g/mol; CAS 910463-68-6) modified with a C18 fatty diacid side chain that enhances albumin binding and extends biological activity. As a GLP-1 receptor agonist, it stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and enhances central and peripheral satiety signaling involved in metabolic regulation.
The rationale for combining these agents lies in their complementary and potentially synergistic mechanisms. Amylin receptor activation reduces caloric intake through satiety pathways and postprandial glucagon suppression, while GLP-1 receptor activation improves glucose regulation, delays gastric emptying, and further promotes appetite control. Together, these pathways provide a multi-target approach to investigating energy balance, body-weight regulation, and glycemic physiology beyond the effects observed with either mechanism alone.
| Compound | MW / Formula | CAS No. | Sequence / Structure | Receptor / Target |
|---|---|---|---|---|
| Cagrilintide (5mg) | ~3934 g/mol | 2295591-85-6 | Long-acting amylin analog; fatty acid-conjugated | Amylin receptor (AMY1–3) agonist; appetite and glucagon regulation |
| Semaglutide (5mg) | 4113.6 g/mol | 910463-68-6 | 29-amino-acid GLP-1 analog with C18 fatty diacid conjugation | GLP-1 receptor agonist; insulin secretion and appetite regulation |
The following compounds operate through distinct, non-overlapping mechanisms that complement this product's research pathways. Each is independently available from the General Peptide catalog.
MOTS-c is a unique 16-amino acid peptide encoded by the mitochondrial genome rather than nuclear DNA. It functions as a potent metabolic regulator and "exercise mimetic" by translocating to the nucleus to activate AMPK, optimizing cellular ener...
NAD+ is a vital dinucleotide coenzyme present in all living cells, central to cellular energy, DNA repair, and signaling. It fuels ATP production and acts as the rate-limiting substrate for Sirtuins, PARPs, and CD38 enzymes. Because NAD+ levels...
HGH Fragment 176-191 is a C-terminal 16-amino acid fragment of human Growth Hormone (residues 176-191) that selectively stimulates lipolysis and inhibits lipogenesis through beta3-adrenergic receptor activation, independent of the GH receptor. ...
This triple-blend combines two Growth Hormone Releasing Hormones (Tesamorelin, CJC-1295) with a selective ghrelin mimetic (Ipamorelin) to maximize pulsatile GH secretion. By targeting pituitary somatotrophs through distinct pathways, it synergi...
5-Amino-1MQ is a potent NNMT (Nicotinamide N-methyltransferase) inhibitor (MW 158.2 g/mol; C10H12N2) that enhances NAD+ biosynthesis and activates sirtuin pathways in adipose tissue. By blocking NNMT, it prevents SAM diversion toward nicotinami...